Business Description
Aytu BioPharma Inc
NAICS : 541714
SIC : 2834
ISIN : US0547548588
Total Employee Number:
83Description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.23 | |||||
Equity-to-Asset | 0.32 | |||||
Debt-to-Equity | 0.62 | |||||
Debt-to-EBITDA | -0.8 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -4.52 | |||||
Beneish M-Score | -3.25 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -45.6 | |||||
3-Year EBITDA Growth Rate | 65.2 | |||||
3-Year EPS without NRI Growth Rate | 69.1 | |||||
3-Year FCF Growth Rate | 65.3 | |||||
3-Year Book Growth Rate | -54.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.26 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.21 | |||||
9-Day RSI | 45.31 | |||||
14-Day RSI | 46.23 | |||||
3-1 Month Momentum % | -13.1 | |||||
6-1 Month Momentum % | -18.89 | |||||
12-1 Month Momentum % | -17.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.12 | |||||
Quick Ratio | 1 | |||||
Cash Ratio | 0.45 | |||||
Days Inventory | 178.35 | |||||
Days Sales Outstanding | 200.71 | |||||
Days Payable | 228.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -67 | |||||
Shareholder Yield % | -24.57 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 64.78 | |||||
Operating Margin % | -12.19 | |||||
Net Margin % | -60.17 | |||||
EBITDA Margin % | -47.98 | |||||
FCF Margin % | -2.37 | |||||
OCF Margin % | 2.96 | |||||
ROE % | -134.73 | |||||
ROA % | -28.05 | |||||
ROIC % | -9.89 | |||||
3-Year ROIIC % | -136.62 | |||||
ROC (Joel Greenblatt) % | -2089.63 | |||||
ROCE % | -55.77 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 21.1 | |||||
PS Ratio | 0.41 | |||||
PB Ratio | 0.63 | |||||
Price-to-Operating-Cash-Flow | 8.27 | |||||
EV-to-EBIT | -0.54 | |||||
EV-to-Forward-EBIT | 2.66 | |||||
EV-to-EBITDA | -0.63 | |||||
EV-to-Forward-EBITDA | 3.79 | |||||
EV-to-Revenue | 0.3 | |||||
EV-to-Forward-Revenue | 0.26 | |||||
EV-to-FCF | -12.77 | |||||
Price-to-GF-Value | 2.38 | |||||
Earnings Yield (Greenblatt) % | -185.19 | |||||
FCF Yield % | -6.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AYTU
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aytu BioPharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 56.599 | ||
| EPS (TTM) ($) | -4.84 | ||
| Beta | -0.4638 | ||
| 3-Year Sharpe Ratio | 0.34 | ||
| 3-Year Sortino Ratio | 0.68 | ||
| Volatility % | 41.47 | ||
| 14-Day RSI | 46.23 | ||
| 14-Day ATR ($) | 0.068221 | ||
| 20-Day SMA ($) | 2.1815 | ||
| 12-1 Month Momentum % | -17.36 | ||
| 52-Week Range ($) | 1.6501 - 3.065 | ||
| Shares Outstanding (Mil) | 10.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aytu BioPharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aytu BioPharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| First quarter earnings conference call for 2027 | 2026-11-13 16:30 | In 110 days | ||
| First quarter earnings results for 2027 | 2026-11-13 | In 109 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-09-23 16:30 | In 59 days | ||
| Annual report for 2026 | 2026-09-23 | In 58 days | ||
| Fourth quarter earnings results for 2026 | 2026-09-23 | In 58 days | ||
| General meeting for 2026 | 2026-07-30 10:00 | In 4 days | ||
| Guidance call for 2026 | 2026-05-28 09:15 | 2.21 (+2.31%) | ||
| Third quarter earnings conference call for 2026 | 2026-05-13 16:30 | 2.30 (-6.12%) | ||
| Third quarter earnings results for 2026 | 2026-05-13 | 2.30 (-6.12%) | ||
| Second quarter earnings conference call for 2026 | 2026-02-03 16:30 | 2.71 (+5.45%) |
Show
Entries
Aytu BioPharma Inc Frequently Asked Questions
What is Aytu BioPharma Inc(AYTU)'s stock price today?
The current price of AYTU is $2.05. The 52 week high of AYTU is $3.07 and 52 week low is $1.65.
When is next earnings date of Aytu BioPharma Inc(AYTU)?
The next earnings date of Aytu BioPharma Inc(AYTU) is 2026-09-23 Est..
Does Aytu BioPharma Inc(AYTU) pay dividends? If so, how much?
Aytu BioPharma Inc(AYTU) does not pay dividend.
Guru Commentaries on NAS:AYTU
No articles.
Press Release
Articles on Aytu BioPharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers